ADVERTISEMENT

Italy to take legal action against vaccine makers over delays

January 24, 2021 10:07 pm | Updated 10:07 pm IST - Milan

Pfizer had said it was slowing supplies to Europe

Italy will take legal action against Pfizer Inc and AstraZeneca over delays in deliveries of COVID-19 vaccines to secure agreed supplies rather than seek damages, Foreign Minister Luigi Di Maio said on Sunday.

“We are working so our vaccine plan programme does not change,” Mr. Di Maio said on RAI state television.

On Saturday, Italian Prime Minister Giuseppe Conte said the delays in vaccine supplies were “unacceptable” and amounted to a serious breach of contractual obligations, adding that Italy would use all available legal tools.

ADVERTISEMENT

Italy will have to rethink its whole vaccination programme if supply problems persist, a senior health official warned.

Asked why he thought the pharmaceutical companies had beenforced to announce reductions, Mr. Di Maio said he believed they had simply bitten off more than they could chew.

“We are activating all channels so the EU Commission does all it can to make these gentlemen respect their contracts,” he said.

ADVERTISEMENT

Pfizer last week said it was temporarily slowing supplies to Europe to make manufacturing changes that would boost output.

On Friday, a senior official told Reuters that AstraZeneca had also informed the European Union it would cut deliveries of its COVID-19 vaccine to the bloc by 60% because of production problems.

The cut in supplies announced by the two companies will put back vaccination of those aged 80 and above in Italy by about four weeks and the rest of the population by about 6-8 weeks, Deputy Health Minister Pierpaolo Sileri said.

“This kind of delay affects the whole of Europe and a good part of the world,” he said.

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT